Compare NSYS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSYS | KPTI |
|---|---|---|
| Founded | 1981 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 47.6M |
| IPO Year | 1996 | 2013 |
| Metric | NSYS | KPTI |
|---|---|---|
| Price | $12.46 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 14.6K | ★ 2.3M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.85 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | $14,371,000.00 | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | $141.67 | ★ N/A |
| Revenue Growth | ★ 7.01 | 0.57 |
| 52 Week Low | $6.50 | $1.80 |
| 52 Week High | $18.01 | $10.99 |
| Indicator | NSYS | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 18.61 |
| Support Level | $11.94 | N/A |
| Resistance Level | $15.35 | $7.46 |
| Average True Range (ATR) | 1.06 | 0.30 |
| MACD | -0.10 | -0.10 |
| Stochastic Oscillator | 7.98 | 3.53 |
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).